Compare MMU & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMU | VALN |
|---|---|---|
| Founded | 1992 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.5M | 537.8M |
| IPO Year | N/A | 2021 |
| Metric | MMU | VALN |
|---|---|---|
| Price | $10.11 | $6.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.75 |
| AVG Volume (30 Days) | 114.4K | ★ 140.2K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 4.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $4.00 |
| Revenue Next Year | N/A | $92.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.46 | $5.43 |
| 52 Week High | $10.71 | $12.25 |
| Indicator | MMU | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 39.49 | 24.85 |
| Support Level | $9.81 | $5.69 |
| Resistance Level | $10.49 | $6.73 |
| Average True Range (ATR) | 0.14 | 0.37 |
| MACD | -0.00 | -0.28 |
| Stochastic Oscillator | 29.99 | 0.18 |
Western Asset Managed Municipals Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is to maximize current income exempted from federal income tax as is consistent with the preservation of principal. The fund predominantly invests in long-term investment grade municipal debt securities issued by state and local governments, political subdivisions, agencies, and public authorities (municipal obligations).
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.